Generic Drugmakers Get U.S. Guidance on Removing REMS

International Pharmaceutical Regulatory Monitor
A A
U.S. Food and Drug Administration (FDA) final guidance on distribution of medication guides allows generic drugmakers to submit a changes-being-effected supplement to eliminate having to adopt a risk evaluation and mitigation strategy (REMS) if the REMS for the brand drug has been removed and includes only a medication guide.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00